Trial Profile
Trial of Treatment of Non-Infectious Intermediate and Posterior Uveitis With Humanized Anti-Tac Antibody Therapy
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 Jan 2017
Price :
$35
*
At a glance
- Drugs Daclizumab (Primary) ; Daclizumab (Primary)
- Indications Intermediate uveitis; Posterior uveitis
- Focus Adverse reactions
- 31 Jan 2017 New trial record